Dec 28, 2025 • The Globe and Mail
BULLISH
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
Oregon-based Stonepine Capital Management sold its entire position in ANI Pharmaceuticals (NASDAQ:ANIP) during the third quarter, totaling 38,597 shares worth $2.52 million. This full exit occurred despite ANI Pharmaceuticals stock being up 49% over the past year with surging revenue and strong third-quarter results. The fund's decision appears to be a capital rotation towards earlier-stage biotech, rather than a vote of no confidence in ANI's fundamentals.
Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in ANI Pharmaceuticals (ANIP) by 41.6% in Q3 2025, selling 22,482 shares and retaining 31,497 shares valued at $2.89 million. Insiders sold 28,001 shares totaling $2.45 million over the last 90 days, while institutions own 76.05% of the stock. ANI Pharmaceuticals exceeded Q3 EPS estimates with $2.04 and saw revenue increase by 53.6% year-over-year, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $102.14.
Dec 22, 2025 • MarketBeat
SOMEWHAT-BEARISH
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling
ANI Pharmaceuticals (NASDAQ:ANIP) experienced a 3.6% mid-day drop following insider selling, specifically by SVP Krista Davis who sold 1,622 shares. Despite this, analyst sentiment remains generally positive, with a "Moderate Buy" rating and an average price target of $102.14. The company also reported strong Q3 earnings, beating expectations with $2.04 EPS and a 53.6% year-over-year revenue increase.
Dec 21, 2025 • MSN
BULLISH
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
This article announces that ANI Pharmaceuticals (ANIP) is scheduled to report its Q1 2025 earnings on May 8, with analysts expecting an average EPS of $0.80. The company's previous earnings surprise history and recent stock performance suggest potential for a beat this quarter. Investors will be watching the upcoming earnings call for further insights.
Dec 19, 2025 • Sahm
SOMEWHAT-BULLISH
ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum
ANI Pharmaceuticals has shown strong share price momentum and year-to-date gains, with analysts suggesting the stock is undervalued based on long-term growth expectations. While the narrative points to a fair value of $109.88, its current P/E ratio of 50.7x appears stretched compared to industry averages, raising questions about whether its growth story can sustain this premium. Sustaining upside will depend on key product momentum and maintaining generic margins amidst increasing competition.
Dec 19, 2025 • MarketBeat
SOMEWHAT-BULLISH
Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP
Squarepoint Ops LLC acquired a new stake of 32,744 shares, valued at $2.14 million, in ANI Pharmaceuticals (NASDAQ:ANIP) during the second quarter. Despite this institutional interest, company insiders have recently sold shares totaling $2.31 million. ANI Pharmaceuticals surpassed Q3 earnings expectations and provided strong FY2025 guidance, leading to a "Moderate Buy" consensus analyst rating with an average target price of $102.14.